Upstream Bio (UPB) Total Non-Current Liabilities (2023)

Upstream Bio (UPB) posted quarterly Total Non-Current Liabilities of $6.5 million for Q4 2023.

Upstream Bio (UPB) Total Non-Current Liabilities (2023) Analysis & Trends

Upstream Bio's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $6.5 million for Q4 2023.

In Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $6.5 million; the TTM figure through Dec 2023 stood at $6.5 million (changed N/A YoY), while the FY2023 annual figure was $6.5 million, changed N/A from the prior year.
Total Non-Current Liabilities for Q4 2023 stood at $6.5 million.
The five-year high for Total Non-Current Liabilities was $6.5 million in Q4 2023, with the low at $6.5 million in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	40.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	1.53 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.88 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.32 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	4.20 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.17 Bn
10	Upstream Bio	387.23 Mn	387.23 Mn	-3.29 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	6.52 Mn